BRIEF published on 11/13/2025 at 18:02, 21 days 12 hours ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 11/13/2025 at 18:02, 21 days 12 hours ago Franchissement de seuils par Heights Capital Management Obligations Convertibles Franchissement De Seuils GenSight Biologics Actions Et Droits De Vote Heights Capital
PRESS RELEASE published on 11/13/2025 at 17:57, 21 days 12 hours ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils GENSIGHT BIOLOGICS SA Heights Capital Management CVI Investments Inc.
BRIEF published on 10/30/2025 at 07:35, 1 month 5 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 10/30/2025 at 07:35, 1 month 5 days ago GenSight Biologics : Feu vert pour un traitement compassionnel aux États-Unis FDA GenSight Biologics NOHL Accès Compassionnel GS010/LUMEVOQ®
PRESS RELEASE published on 10/30/2025 at 07:30, 1 month 5 days ago Informations privilégiées / Autres communiqués GenSight Biologics a obtenu les autorisations réglementaires pour un traitement compassionnel aux États-Unis avec GS010/LUMEVOQ, visant la Neuropathie Optique Héréditaire de Leber FDA GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ Traitement Compassionnel
BRIEF published on 09/29/2025 at 23:05, 2 months 5 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
BRIEF published on 09/29/2025 at 23:05, 2 months 5 days ago GenSight Biologics annonce ses résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie GenSight Biologics Programmes D'accès Précoce
PRESS RELEASE published on 09/29/2025 at 23:00, 2 months 5 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie résultats financiers du premier semestre 2025 : gestion optimisée de trésorerie, financement post-clôture, transfert de fabrication, protocole d'étude soumis à l'ANSM Résultats Financiers Financement Trésorerie GenSight Biologics Étude ANSM
PRESS RELEASE published on 09/29/2025 at 23:00, 2 months 5 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
Published on 12/05/2025 at 02:35, 4 hours 2 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 37 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 32 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 37 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 7 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 46 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 12 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 22 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 27 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 22 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
